Articles with public access mandates - Joseph M Unger, PhD, MSLearn more
Not available anywhere: 3
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer—Reply
DL Hershman, JM Unger
JAMA oncology 2 (5), 686-687, 2016
Mandates: US National Institutes of Health
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL.
JE Amengual, P Reagan, H Li, H Saeed, R Vaidya, JM Unger, A Danilov, ...
Hematological Oncology 41, 2023
Mandates: US National Institutes of Health
Racial and Ethnic Disparity in Preference-Weighted Quality of Life: Findings from the Selenium and Vitamin E Cancer Prevention Trial
MC Rock, R Vaidya, C Till, JM Unger, D Hershman, S Ramsey, ...
Population Health Management, 2023
Mandates: US National Institutes of Health
Available somewhere: 140
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy
HCF Moore, JM Unger, KA Phillips, F Boyle, E Hitre, D Porter, PA Francis, ...
New England Journal of Medicine 372 (10), 923-932, 2015
Mandates: US National Institutes of Health
Role of clinical trial participation in cancer research: barriers, evidence, and strategies
JM Unger, E Cook, E Tai, A Bleyer
American Society of Clinical Oncology educational book. American Society of …, 2016
Mandates: US National Institutes of Health
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group
KS Albain, JM Unger, JJ Crowley, CA Coltman, DL Hershman
JNCI: Journal of the National Cancer Institute 101 (14), 984-992, 2009
Mandates: US National Institutes of Health
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma
PJ Stiff, JM Unger, JR Cook, LS Constine, S Couban, DA Stewart, ...
New England Journal of Medicine 369 (18), 1681-1690, 2013
Mandates: US National Institutes of Health, Canadian Cancer Society
Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ...
JAMA oncology 5 (10), e191870-e191870, 2019
Mandates: US National Institutes of Health
Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation
JM Unger, R Vaidya, DL Hershman, LM Minasian, ME Fleury
JNCI: Journal of the National Cancer Institute 111 (3), 245-255, 2019
Mandates: US National Institutes of Health
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic …
M Lambertini, HCF Moore, RCF Leonard, S Loibl, P Munster, M Bruzzone, ...
Journal of clinical oncology 36 (19), 1981-1990, 2018
Mandates: US National Institutes of Health, UK Medical Research Council
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study …
DO Persky, JM Unger, CM Spier, B Stea, M LeBlanc, MJ McCarty, ...
Journal of clinical oncology 26 (14), 2258-2263, 2008
Mandates: US National Institutes of Health
Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer
DL Hershman, JM Unger, JD Wright, S Ramsey, C Till, CM Tangen, ...
JAMA oncology 2 (4), 453-461, 2016
Mandates: US National Institutes of Health
Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial
DL Hershman, JM Unger, H Greenlee, JL Capodice, DL Lew, AK Darke, ...
Jama 320 (2), 167-176, 2018
Mandates: US National Institutes of Health
Patient income level and cancer clinical trial participation
JM Unger, DL Hershman, KS Albain, CM Moinpour, JA Petersen, K Burg, ...
Journal of Clinical Oncology 31 (5), 536-542, 2013
Mandates: US National Institutes of Health
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group
SH Bernstein, JM Unger, M LeBlanc, J Friedberg, TP Miller, RI Fisher
Journal of clinical oncology 27 (1), 114-119, 2009
Mandates: US National Institutes of Health
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy
DL Hershman, JM Unger, KD Crew, LM Minasian, D Awad, CM Moinpour, ...
Journal of Clinical Oncology 31 (20), 2627-2633, 2013
Mandates: US National Institutes of Health, UK Medical Research Council
Comparison of survival outcomes among cancer patients treated in and out of clinical trials
JM Unger, WE Barlow, DP Martin, SD Ramsey, M LeBlanc, R Etzioni, ...
Journal of the National Cancer Institute 106 (3), dju002, 2014
Mandates: US National Institutes of Health
Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials
DL Hershman, C Till, JD Wright, D Awad, SD Ramsey, WE Barlow, ...
Journal of Clinical Oncology 34 (25), 3014-3022, 2016
Mandates: US National Institutes of Health
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430
JA Sosman, J Moon, RJ Tuthill, JA Warneke, JT Vetto, BG Redman, ...
Cancer 117 (20), 4740-4746, 2011
Mandates: US National Institutes of Health
Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221)
CB Ambrosone, GR Zirpoli, AD Hutson, WE McCann, SE McCann, ...
Journal of Clinical Oncology 38 (8), 804-814, 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program